Attovia Therapeutics, Inc.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $450.0K | — | — | $0 | — |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | — | $18.9M | — | — | $13.6M | — |
| SG&A Expense | — | $3.3M | — | — | $3.0M | — |
| Operating Income | — | $-21.8M | — | — | $-16.6M | — |
| Operating Margin | — | -4,845.1% | — | — | — | — |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — |
| Net Income | — | $-20.7M | $-18.7M | — | $-14.4M | $-15.2M |
| Net Margin | — | -4,597.1% | — | — | — | — |
| EPS (Basic) | — | $-4.88 | — | — | $-3.71 | — |
| EPS (Diluted) | — | $-4.88 | — | — | $-3.71 | — |
| Shares Outstanding (Basic) | 45.7M | 4.2M | — | 4.5M | 3.9M | — |
| Shares Outstanding (Diluted) | 45.7M | 4.2M | — | 4.5M | 3.9M | — |
| Dividends Per Share | — | — | — | — | — | — |